Song Hanjoon M, Nacamuli Randall P, Xia Wei, Bari Ali S, Shi Yun-Ying, Fang Tony D, Longaker Michael T
The Department of Surgery, Stanford University School of Medicine, Stanford, California 94305-5148, USA.
J Cell Physiol. 2005 Jan;202(1):255-62. doi: 10.1002/jcp.20115.
Retinoic acid has been shown to adversely affect craniofacial development. Cleft palate and craniosynostosis are two examples of craniofacial defects associated with prenatal exposure to this agent. Although the effects of retinoic acid on cephalic neural crest-derived tissues have previously been studied, the specific effects of retinoic acid on the cellular biology of osteoblasts remain unclear. The purpose of this study was to analyze in detail the effects of pharmacologic doses of retinoic acid on the differentiation and proliferation of osteoblasts derived from an intramembranous source. Primary rat calvarial osteoblasts were established in culture and treated with 1 or 10 microM all-trans-retinoic acid. Retinoic acid treatment markedly increased expression of osteopontin up to 48 h after stimulation. Consistent with this early stage of differentiation, both mRNA and protein analysis of FGF receptor isoforms demonstrated a switch in predominance from fibroblast growth factor receptor 2 (fgfr2) to fgfr1. Analysis of PCNA protein confirmed inhibition of proliferation by retinoic acid. To determine whether these alterations in osteoblast biology would lead to increased differentiation, we examined short term [alkaline phosphatase (AP) activity] and long term (von Kossa staining) surrogates of bone formation in vitro. These assays confirmed that retinoic acid increased osteogenesis, with a 4-fold increase in bone nodule formation in cells treated with 10 microM retinoic acid after 28 days. Overall, our results demonstrated that pharmacologic doses of all-trans-retinoic acid decreased osteoblast proliferation and increased differentiation, suggesting that retinoic acid may effect craniofacial development by pathologically enhancing osteogenesis.
维甲酸已被证明会对颅面发育产生不利影响。腭裂和颅缝早闭是与产前接触该药物相关的颅面缺陷的两个例子。尽管此前已经研究了维甲酸对头部神经嵴衍生组织的影响,但维甲酸对成骨细胞细胞生物学的具体影响仍不清楚。本研究的目的是详细分析药理剂量的维甲酸对膜内源性成骨细胞分化和增殖的影响。将原代大鼠颅骨成骨细胞进行培养,并分别用1或10微摩尔的全反式维甲酸处理。维甲酸处理在刺激后长达48小时显著增加骨桥蛋白的表达。与这种早期分化阶段一致,对成纤维细胞生长因子受体亚型的mRNA和蛋白质分析表明,优势从成纤维细胞生长因子受体2(fgfr2)转变为fgfr1。对增殖细胞核抗原蛋白的分析证实维甲酸抑制了增殖。为了确定成骨细胞生物学中的这些改变是否会导致分化增加,我们在体外检查了骨形成的短期(碱性磷酸酶(AP)活性)和长期(冯·科萨染色)替代指标。这些试验证实维甲酸增加了成骨作用,在用10微摩尔维甲酸处理的细胞中,28天后骨结节形成增加了4倍。总体而言,我们的结果表明,药理剂量的全反式维甲酸降低了成骨细胞增殖并增加了分化,这表明维甲酸可能通过病理性增强成骨作用来影响颅面发育。